Loading…
Emergent BioSolutions Inc. is projected to rise to $7.37 by 2027, a +2% move from its current price of $7.22. EBS is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/2/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 3 | $7.07 | $7.22 | $7.38 | +0.04% |
| Aug 4 | $7.01 | $7.23 | $7.45 | +0.07% |
| Aug 5 | $6.96 | $7.23 | $7.51 | +0.11% |
| Aug 6 | $6.92 | $7.23 | $7.55 | +0.14% |
| Aug 7 | $6.89 | $7.23 | $7.60 | +0.18% |
| Aug 8 | $6.86 | $7.24 | $7.63 | +0.22% |
| Aug 9 | $6.83 | $7.24 | $7.67 | +0.25% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $6.83 | $7.24 | $7.67 | +0.25% |
| Week 2 | $6.69 | $7.26 | $7.87 | +0.50% |
| Week 3 | $6.58 | $7.27 | $8.04 | +0.75% |
| Week 4 | $6.50 | $7.29 | $8.19 | +1.01% |
| Week 5 | $6.42 | $7.31 | $8.32 | +1.26% |
| Week 6 | $6.36 | $7.33 | $8.44 | +1.51% |
| Week 7 | $6.31 | $7.35 | $8.56 | +1.77% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Emergent BioSolutions Inc. is a life sciences company that provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally.
It operates through Commercial Products, MCM Products, and All Other Revenues segments.
Emergent BioSolutions was incorporated in 1998 and is headquartered in Gaithersburg, Maryland. The company offers ACAM2000, a smallpox and mpox vaccine; Anthrax Immune Globulin Intravenous (ANTHRASIL), a polyclonal antibody therapeutic for the treatment of inhalational anthrax; Botulism Antitoxin Heptavalent (BAT), an equine plasma antitoxin for the treatment of symptomatic botulism; BioThrax, an anthrax vaccine; CYFENDUS, a vaccine for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; Ebanga, a monoclonal antibody for the treatment of infection caused by Orthoebolavirus zairense; Raxibacumab injection, a monoclonal antibody therapeutic for the treatment and prophylaxis of inhalational anthrax due to Bacillus anthracis; TEMBEXA, an oral antiviral for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; and CNJ-016, a polyclonal antibody therapeutic to address complications from smallpox vaccination. It also provides NARCAN and KLOXXADO nasal sprays for the emergency treatment of known or suspected opioid overdose.
In addition, the company offers contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, analytical development, and suite reservation services. Emergent BioSolutions Inc. was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
Emergent BioSolutions Inc. (EBS) currently trades at $7.26 per share and has a market capitalization of $374.59M, ranking 3096 by size.
The stock’s near-term technical picture is bearish, with RSI14 at 40 and the price trading below the SMA50 of $8.18 and the SMA200 of $9.68.
The 30-day price range spans $6.18 to $8.53, with near-term support at $7.50 and resistance at $8.53. The longer-term forecast shows upside potential, with the Avg price gradually rising over time toward higher levels and longer horizons.
A major floor 12.1% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.0% away) — a key level to hold.
The nearest ceiling, 18.1% above — a clean break opens room to run.
A major ceiling 31.6% above — clearing it would confirm fresh momentum.
Key EBS support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of EBS market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $7.29 | Sell | $7.30 | Sell |
| MA 10 | $7.42 | Sell | $7.41 | Sell |
| MA 20 | $7.69 | Sell | $7.62 | Sell |
| MA 50 | $8.07 | Sell | $7.97 | Sell |
| MA 100 | $8.19 | Sell | $8.40 | Sell |
| MA 200 | $9.61 | Sell | $8.73 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 35.70 | Neutral |
| Stoch RSI (14) | 3.56 | Buy |
| CCI (20) | -105.18 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.03 | Sell |
| ROC (12) | -8.49 | Sell |
| Bollinger %B (20,2) | 0.16 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.38 | Sell |
| Awesome (5,34) | -0.60 | Sell |
| Ultimate (7,14,28) | 25.31 | Buy |
| Momentum (10) | -0.41 | Sell |
| Aroon Osc (25) | -96.00 | Sell |
| Hull MA (9) | 7.23 | Sell |
| ADX (14) | 17.06 | Neutral |
| ATR (14) | 0.13 | Info |
The 30-day technical picture is bearish, with sentiment labeled as BEARISH and RSI14 at 40. The price remains pressured by near-term resistance below key moving averages, suggesting limited upside in the immediate term.
Price action sits below the SMA50 of $8.18 and the SMA200 of $9.68, reinforcing the cautious stance. The stock’s 30-day range is $6.18 to $8.53, placing the current price near support around $7.50 and just under resistance at $8.53.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $7.22 | $7.22 | $9.26 | 0% | Neutral | |
| $5.99 | $7.37 | $9.53 | +2% | Neutral | |
| $6.81 | $8.57 | $11.42 | +19% | Neutral | |
| $8.04 | $10.31 | $14.08 | +43% | Bullish | |
| $8.27 | $10.78 | $15.03 | +49% | Bullish | |
| $8.82 | $11.65 | $16.53 | +61% | Bullish | |
| $8.75 | $11.71 | $16.89 | +62% | Bullish | |
| $8.83 | $11.98 | $17.53 | +66% | Bullish | |
| $10.02 | $13.76 | $20.40 | +91% | Bullish | |
| $10.84 | $15.04 | $22.59 | +108% | Bullish | |
| $13.56 | $19.79 | $31.33 | +174% | Bullish | |
| $24.62 | $39.13 | $66.92 | +442% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $7.22 | $7.22 | $8.75 | +0.00% |
| September 2026 | $6.21 | $7.30 | $8.80 | +1.17% |
| October 2026 | $6.31 | $7.46 | $9.07 | +2.13% |
| November 2026 | $6.43 | $7.64 | $9.35 | +2.45% |
| December 2026 | $6.31 | $7.52 | $9.26 | -1.62% |
Click any year to see its month-by-month EBS forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, EBS is projected to trade between $7.22 and $9.26, averaging $7.22 — a potential gain of 0% from today's $7.22. A consolidation phase looks the most probable path here.
Emergent BioSolutions Inc.'s 2027 outlook centres on $7.37, within a $5.99 to $9.53 range. That is up +2% on the projected 2026 average. That marks a +2% change versus current levels. Price action looks broadly range-bound.
By 2028, EBS could reach as high as $11.42, with a base case around $8.57 and support toward $6.81 — roughly +19% from $7.22. A consolidation phase looks the most probable path here.
Expect EBS to range from $8.04 to $14.08 through 2029. The $10.31 average target implies a +43% move from current prices. That is up +20% on the projected 2028 average. Momentum favours further upside here.
The EBS price prediction for 2030 points to an average of $10.78 (low $8.27, high $15.03) — a potential gain of +49% on today's $7.22. Buyers look set to stay in control over this stretch.
In 2031, EBS is projected to trade between $8.82 and $16.53, averaging $11.65 — a potential gain of +61% from today's $7.22. That is up +8% on the projected 2030 average. Momentum favours further upside here.
Emergent BioSolutions Inc.'s 2032 outlook centres on $11.71, within a $8.75 to $16.89 range. That is up +1% on the projected 2031 average. That marks a +62% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, EBS could reach as high as $17.53, with a base case around $11.98 and support toward $8.83 — roughly +66% from $7.22. Momentum favours further upside here.
Expect EBS to range from $10.02 to $20.40 through 2034. The $13.76 average target implies a +91% move from current prices. That is up +15% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The EBS price prediction for 2035 points to an average of $15.04 (low $10.84, high $22.59) — a potential gain of +108% on today's $7.22. Momentum favours further upside here.
In 2040, EBS is projected to trade between $13.56 and $31.33, averaging $19.79 — a potential gain of +174% from today's $7.22. That is up +32% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Emergent BioSolutions Inc.'s 2050 outlook centres on $39.13, within a $24.62 to $66.92 range. That is up +98% on the projected 2040 average. That marks a +442% change versus current levels. Momentum favours further upside here.
Investing $1,000 in EBS today (≈ 138.504155 EBS) could be worth
$5,419.74
+$4,419.74 (+442%) by 2050 · US Dollar
Based on the average projected EBS price of $39.13 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in EBSwould be worth at today's price.
$1,000 invested in EBS on Jul 31, 2025 (≈ 170.068024 EBS) would be worth
$1,227.89
+$227.89 (+22.8%) today · 1.23× · US Dollar
Based on a EBS entry price of $5.88 vs. today's $7.22.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $7.26 | $994.49 | -0.6% |
| 1 month ago | $8.28 | $871.98 | -12.8% |
| 3 months ago | $8.47 | $852.42 | -14.8% |
| 6 months ago | $11.71 | $616.57 | -38.3% |
| 1 year ago | $5.88 | $1,227.89 | +22.8% |
| All time (5.0y) ago | $63.38 | $113.92 | -88.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our EBS forecast.
Our base-case forecast reaches $14.00 around 2035.
Implied market cap at $14.00: $722.35M
The multi-year forecast projects meaningful upside from the current level, with the Avg price climbing through successive years and the ROI expanding accordingly.
Key milestones include 2026 with an Avg of $7.26 and a max of $9.38 (ROI 0, sentiment NEUTRAL), 2027 with Avg $7.56 and max $9.90 (ROI 4.1, NEUTRAL), and 2028 with Avg $9.04 and max $12.25 (ROI 24.5, BULLISH).
By 2030, the Avg is $11.60 with a max of $16.51 (ROI 59.8, BULLISH); 2031 sees Avg $12.57 and max $18.25 (ROI 73.2, BULLISH); 2032 Avg $12.63 and max $18.65 (ROI 73.9, BULLISH); and 2033 Avg $13.08 with max $19.63 (ROI 80.2, BULLISH).
The rise continues through 2034 (Avg $15.28; max $23.27; ROI 110.5) and 2035 (Avg $16.79; max $25.92; ROI 131.2), with the long-term trajectory culminating in 2040 Avg $22.63 (ROI 211.7) and 2050 Avg $44.87 (ROI 518.1), the latter with a max of $79.78. These figures indicate substantial upside over the longer horizon, but they remain estimates rather than guarantees and come with inherent investment risk.
Tap a question to reveal the answer.
2030: avg price $11.60, min $8.76, max $16.51; ROI 59.8%; sentiment BULLISH.
Longer-term forecasts suggest upside, with avg prices rising to $11.60 by 2030 and $44.87 by 2050 and ROI up to 518.1%. These are estimates and not guarantees, and risk remains.
The forecast shows a max of $79.78 by 2050, which does not reach $100 within the provided horizon.
Current price is $7.26 and market capitalization is $374.59M.
The 30-day range is $6.18 to $8.53.
Emergent BioSolutions Inc. Community Discussion
0Share your Emergent BioSolutions Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.